Talphera (TLPH) 10-Q8 May 142014 Q1 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2014	Apr. 17, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'ACRX	'
Entity Registrant Name	'ACELRX PHARMACEUTICALS INC	'
Entity Central Index Key	'0001427925	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	43,316,104

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Current Assets:	'	'
Cash and cash equivalents	$77,587	$88,401	[1]
Short-term investments	15,289	15,262	[1]
Prepaid expenses and other current assets	1,091	897	[1]
Total current assets	93,967	104,560	[1]
Property and equipment, net	6,160	5,179	[1]
Restricted cash	250	250	[1]
Other assets	40	42	[1]
Total Assets	100,417	110,031	[1]
Current Liabilities:	'	'
Accounts payable	2,185	2,341	[1]
Accrued liabilities	1,895	3,904	[1]
Deferred revenue	528	623	[1]
Total current liabilities	4,608	6,868	[1]
Deferred rent	156	188	[1]
Long-term debt	14,492	14,364	[1]
Deferred revenue	2,007	2,007	[1]
Contingent put option liability	296	334	[1]
Warrant liability	13,795	13,111	[1]
Total liabilities	35,354	36,872	[1]
Stockholders' Equity:	'	'
Common stock, $0.001 par value-100,000,000 shares authorized as of March 31, 2014 and December 31, 2013; 43,316,104 and 43,050,580 shares issued and outstanding as of March 31, 2014 and December 31, 2013	43	43	[1]
Additional paid-in capital	220,103	218,568	[1]
Accumulated deficit	-155,084	-145,453	[1]
Accumulated other comprehensive income	1	1	[1]
Total stockholders' equity	65,063	73,159	[1]
Total Liabilities and Stockholders' Equity	$100,417	$110,031	[1]

[1]	The condensed balance sheet as of December 31, 2013 has been derived from the audited financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2013.

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]	'	'
Common stock, par value	$0.00	$0.00	[1]
Common stock, shares authorized	100,000,000	100,000,000	[1]
Common stock, shares issued	43,316,104	43,050,580	[1]
Common stock, shares outstanding	43,316,104	43,050,580	[1]

[1]	The condensed balance sheet as of December 31, 2013 has been derived from the audited financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2013.

Condensed_Statements_of_Compre

Condensed Statements of Comprehensive Loss (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Revenue:	'	'
Collaboration agreement	$95	'
Research grant	0	940
Total revenue	95	940
Operating expenses:	'	'
Research and development	4,711	9,318
General and administrative	3,925	2,191
Total operating expenses	8,636	11,509
Loss from operations	-8,541	-10,569
Interest expense	-472	-454
Interest income and other income (expense), net	-618	-1,739
Net loss	-9,631	-12,762
Other comprehensive loss:	'	'
Unrealized gains (losses) on available-for-sale securities	'	-2
Comprehensive loss	($9,631)	($12,764)
Net loss per share of common stock, basic and diluted	($0.22)	($0.34)
Shares used in computing net loss per share of common stock, basic and diluted	43,190,409	37,133,358

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014		Mar. 31, 2013
Cash flows from operating activities:	'		'
Net loss	($9,631)		($12,762)
Adjustments to reconcile net loss to net cash used in operating activities:	'		'
Depreciation and amortization	162		141
Amortization of premium/discount on investments, net	72		29
Interest expense related to debt financing	131		133
Stock-based compensation	975		757
Revaluation of put option and PIPE warrant liabilities	646		1,755
Changes in operating assets and liabilities:	'		'
Prepaid expenses and other assets	-195		-83
Restricted cash	'		-45
Accounts payable	-156		1,706
Accrued liabilities	-2,012		-1,277
Deferred revenue	-95		'
Deferred rent	-29		-26
Net cash used in operating activities	-10,132		-9,672
Cash flows from investing activities:	'		'
Purchase of property and equipment	-1,143		-52
Purchase of investments	-1,359		-8,365
Proceeds from maturity of investments	1,260		9,045
Net cash (used in) provided by investing activities	-1,242		628
Cash flows from financing activities:	'		'
Payment of long-term debt	'		-1,893
Net proceeds from issuance of common stock through equity plans and exercise of warrants	560		84
Net cash provided by (used in) financing activities	560		-1,809
Net decrease in cash and cash equivalents	-10,814		-10,853
Cash and cash equivalents-Beginning of period	88,401	[1]	47,932
Cash and cash equivalents-End of period	$77,587		$37,079

[1]	The condensed balance sheet as of December 31, 2013 has been derived from the audited financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2013.

Condensed_Statements_of_Cash_F1

Condensed Statements of Cash Flows (Parenthetical) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Statement Of Cash Flows [Abstract]	'	'
Purchases of property and equipment included in Accrued included liabilities	$420,000	$0

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies	3 Months Ended
Organization and Summary of Significant Accounting Policies	Mar. 31, 2014
Accounting Policies [Abstract]	'
Organization and Summary of Significant Accounting Policies	'
	1. Organization and Summary of Significant Accounting Policies
	The Company
	AcelRx Pharmaceuticals, Inc., or the Company or AcelRx, was incorporated in Delaware on July 13, 2005 as SuRx, Inc., and in January 2006, the Company changed its name to AcelRx Pharmaceuticals, Inc. The Company’s operations are based in Redwood City, California.
	AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx intends to commercialize its product candidates in the United States and license the development and commercialization rights to its product candidates for sale outside of the United States through strategic partnerships and collaborations. The Company’s lead product candidate, Zalviso^TM, formerly known as the Sufentanil NanoTab patient-controlled analgesia, or PCA, System, or ARX-01. The New Drug Application, or NDA, for Zalviso is currently under review by the FDA. The proposed indication for Zalviso is for the management of moderate-to-severe acute pain in adult patients in the hospital setting. In addition, in December 2013, the Company entered into a collaboration agreement with Grünenthal, a European-based pharmaceutical company, for the commercialization of Zalviso in Europe and Australia. We anticipate the filing of the Marketing Authorization Application, or MAA, for Zalviso under the centralized procedure in the European Union, or EU, in mid-2014.
	The Company has incurred recurring operating losses and negative cash flows from operating activities since inception and expects to continue to incur negative cash flows until its product candidates are approved for marketing in the United States and other countries, in which it has and intends to license its products, which may never occur. In previous years, prior to the completion of the clinical development program for Zalviso and the commercial collaboration of Zalviso, AcelRx was considered a development stage company.
	The Company has one business activity, which is the development and commercialization of product candidates for the treatment of pain, and a single reporting and operating unit structure.
	Basis of Presentation
	The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and the rules and regulations of the U.S. Securities and Exchange Commission, or SEC. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.
	Operating results for the three months ended March 31, 2014, are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. The condensed balance sheet as of December 31, 2013, was derived from the Company’s audited financial statements as of December 31, 2013, included in the Company’s Annual Report on Form 10-K filed with the SEC. These financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, which includes a broader discussion of the Company’s business and the risks inherent therein.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements and accompanying notes. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

	Newly Adopted Accounting Pronouncements
	There have been no recent accounting pronouncements or changes in accounting pronouncements during the three months ended March 31, 2014, as compared to the recent accounting pronouncements described in the Company’s Form 10-K for the year ended December 31, 2013, that are of significance, or potential significance to the Company.

Investments_and_Fair_Value_Mea

Investments and Fair Value Measurement	3 Months Ended
Investments and Fair Value Measurement	Mar. 31, 2014
Text Block [Abstract]	'
Investments and Fair Value Measurement	'
	2. Investments and Fair Value Measurement
	Investments
	The Company classifies its marketable securities as available-for-sale and records its investments at fair value. Available-for-sale securities are carried at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income. Marketable securities which have maturities beyond one year as of the end of the reporting period are classified as non-current.
	The table below summarizes the Company’s cash, cash equivalents and investments (in thousands):


			As of March 31, 2014
			Amortized Cost			Gross Unrealized			Gross Unrealized			Fair
			Amortized Cost			Gains			Losses			Value
	Cash and cash equivalents:
	Cash		$	77,582		$	—		$	—		$	77,582
	Money market funds			5			—			—			5

	Total cash and cash equivalents			77,587			—			—			77,587
	Marketable securities:
	U.S. government agency securities			15,288			1			—		$	15,289

	Total marketable securities			15,288			1			—		$	15,289

	Total cash, cash equivalents and investments		$	92,875		$	1		$	—		$	92,876


			As of December 31, 2013
			Amortized Cost			Gross Unrealized			Gross Unrealized			Fair
			Amortized Cost			Gains			Losses			Value
	Cash and cash equivalents:
	Cash		$	88,390		$	—		$	—		$	88,390
	Money market funds			11			—			—			11

	Total cash and cash equivalents			88,401			—			—		$	88,401
	Marketable securities:
	U.S. government agency securities			15,261			1			—			15,262

	Total marketable securities			15,261			1			—		$	15,262

	Total cash, cash equivalents and investments		$	103,662		$	1		$	—		$	103,663

	As of March 31, 2014 and December 31, 2013, none of the available-for-sale securities held by the Company had material unrealized losses. There were no other-than-temporary impairments for these securities at March 31, 2014 or December 31, 2013. No gross realized gains or losses were recognized on the available-for-sale securities and, accordingly, there were no amounts reclassified out of accumulated other comprehensive income to earnings during the three months ended March 31, 2014 and 2013.
	As of March 31, 2014 and December 31, 2013, the contractual maturity of all investments held was less than one year.
	Fair Value Measurement
	The Company’s financial instruments consist of Level I and Level II assets and Level III liabilities. Level I securities include highly liquid money market funds and are valued based on quoted market prices. For Level II instruments, the Company estimates fair value by utilizing third party pricing services in developing fair value measurements where fair value is based on valuation methodologies such as models using observable market inputs, including benchmark yields, reported trades, broker/dealer quotes, bids, offers and other reference data. Such Level II instruments typically include U.S. treasury and U.S. government agency obligations. As of March 31, 2014 and December 31, 2013, the Company held, in addition to Level I and Level II assets, a contingent put option liability associated with the Company’s Amended and Restated Loan and Security Agreement, or the Amended Loan Agreement, with Hercules Technology II, L.P. and Hercules Technology Growth Capital, Inc., collectively referred to as Hercules, which amends and restates the loan and security agreement with Hercules dated as of June 29, 2011, or the Original Loan Agreement, and which was classified as a Level III liability. See Note 5 “Long-Term Debt,” for further description. The Company’s estimate of fair value of the contingent put option liability was determined by using a risk-neutral valuation model, wherein the fair value of the underlying debt facility is estimated both with and without the presence of the default provisions, holding all other assumptions constant. The resulting difference between the two estimated fair values is the estimated fair value of the default provisions, or the contingent put option. Changes to the estimated fair value of these liabilities are recorded in interest income and other income (expense), net in the condensed statements of comprehensive loss. The fair value of the underlying debt facility is estimated by calculating the expected cash flows in consideration of an estimated probability of default and expected recovery rate in default, and discounting such cash flows back to the reporting date using a risk-free rate. As of March 31, 2014 and December 31, 2013, the Company also held a Level III liability associated with warrants, or PIPE warrants, issued in connection with the Company’s private placement equity offering, completed in June 2012. The PIPE warrants are considered a liability and are valued using the Black-Scholes option-pricing model, the inputs for which include exercise price of the PIPE warrants, market price of the underlying common shares, expected term, volatility based on a group of the Company’s peers and the risk-free rate corresponding to the expected term of the PIPE warrants. Changes to any of the inputs can have a significant impact to the estimated fair value of the PIPE warrants.
	The following table sets forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands):


			As of March 31, 2014
			Fair Value			Level I			Level II			Level III
	Assets
	Money market funds		$	5		$	5		$	—		$	—
	U.S. government agency obligations			15,289			—			15,289			—

	Total assets measured at fair value		$	15,294		$	5		$	15,289		$	—

	Liabilities
	PIPE warrants		$	13,795			—			—		$	13,795
	Contingent put option liability			296			—			—			296

	Total liabilities measured at fair value		$	14,091		$	—		$	—		$	14,091


			As of December 31, 2013
			Fair Value			Level I			Level II			Level III
	Assets
	Money market funds		$	11		$	11		$	—		$	—
U.S. government agency obligations			15,262			—			15,262			—

Total assets measured at fair value		$	15,273		$	11		$	15,262		$	—

Liabilities
PIPE warrants		$	13,111			—			—		$	13,111
Contingent put option liability		$	334			—			—		$	334

Total liabilities measured at fair value		$	13,445		$	—		$	—		$	13,445

The following table sets forth the assumptions used in the Black-Scholes option-pricing model to estimate the fair value of the PIPE warrants as of March 31, 2014:


Market price		$	12.01
Exercise price		$	3.4
Risk-free interest rate			0.9	%
Expected volatility			64	%
Expected life (in years)			3.7
Expected dividend yield			0	%

The following table sets forth the assumptions used in the Black-Scholes option-pricing model to estimate the fair value of the PIPE warrants as of December 31, 2013:


Market price		$	11.31
Exercise price		$	3.4
Risk-free interest rate			1.27	%
Expected volatility			69	%
Expected life (in years)			3.92
Expected dividend yield			0	%
The following tables set forth a summary of the changes in the fair value of the Company’s Level III financial liabilities for the three months ended March 31, 2014 and March 31, 2013 (in thousands):


		Three Months
		Ended
		March 31,
		2014
Fair value—beginning of period		$	13,445
Change in fair value of PIPE warrants			684
Change in fair value of contingent put option associated with Amended Loan Agreement with Hercules			(38	)

Fair value—end of period		$	14,091


		Three Months
		Ended
		March 31,
		2013
Fair value—beginning of period		$	7,500
Change in fair value of PIPE warrants			1,776
Change in fair value of contingent put option associated with Original Loan Agreement with Hercules			(22	)

Fair value—end of period		$	9,254

Research_Grant_Agreement

Research Grant Agreement	3 Months Ended
Research Grant Agreement	Mar. 31, 2014
Research And Development [Abstract]	'
Research Grant Agreement	'
	3. Research Grant Agreement
	In May 2011, AcelRx received a grant from the US Army Medical Research and Materiel Command, or USAMRMC, in which the USAMRMC granted $5.6 million to the Company in order to support the development of a new product candidate, ARX-04, a sufentanil tablet for the treatment of moderate-to-severe acute pain. Under the terms of the grant, the USAMRMC reimbursed the Company for development, manufacturing and clinical costs necessary to prepare for and complete the planned Phase 2 dose-finding trial in a study of acute moderate-to-severe pain, and to prepare to enter Phase 3 development. The grant gives the USAMRMC the option to extend the term of the grant and provide additional funding for the research. As of December 31, 2013, the full amount of the grant, $5.6 million, had been received and recognized as revenue.
	Revenue is recognized based on expenses incurred by AcelRx in conducting research and development activities set forth in the agreement. Revenue attributable to the research and development performed under the USAMRMC grant was $0 and $940,000 for the three months ended March 31, 2014 and 2013, respectively.

Collaboration_Agreement

Collaboration Agreement	3 Months Ended
Collaboration Agreement	Mar. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Collaboration Agreement	'
	4. Collaboration Agreement
	On December 16, 2013, AcelRx and Grünenthal GmbH, or Grünenthal, entered into a Collaboration and License Agreement (the “License Agreement”) and related Manufacture and Supply Agreement (the “Manufacturing Agreement” and together with the License Agreement, the “Grünenthal Agreements”). The License Agreement grants Grünenthal rights to commercialize Zalviso in the EU, Switzerland, Liechtenstein, Iceland, Norway and Australia, for pain treatment within or dispensed by hospitals, hospices, nursing homes and other medically-supervised settings. Under the Supply Agreement, the Company will exclusively manufacture and supply Zalviso to Grünenthal for sale in their territories.

	License Agreement
	Under the terms of the License Agreement, Grünenthal has the exclusive right to commercialize Zalviso in their territories. The Company retains control of clinical development, and together with Grünenthal will be responsible for certain development activities. The Company will not receive separate payment for such development activities. Grünenthal is responsible for marketing approval applications and other regulatory filings relating to the sufentanil drug cartridge for Zalviso, while the Company is responsible for the CE Mark and other regulatory filings relating to the device portions.
	The Company received an upfront non-refundable cash payment of $30.0 million, and is eligible to receive up to $220.0 million in additional payments contingent upon research, development, regulatory and manufacturing efforts and specified net sales target milestones. Grünenthal will also make tiered royalty and supply and trademark fee payments in the mid-teens up to the mid-twenties percent range on net sales of Zalviso.
	Unless earlier terminated, the License Agreement continues in effect until the expiration of the obligation of Grünenthal to make royalty and supply and trademark fee payments, which supply and trademark fee continues for so long as the Company continues to supply Zalviso to Grünenthal. The License Agreement is subject to earlier termination in the event the parties mutually agree, by a party in the event of an uncured material breach by the other party, upon the bankruptcy or insolvency of either party, or by Grünenthal for convenience.
	Manufacturing Agreement
	Under the terms of the Manufacturing Agreement, the Company will manufacture and supply Zalviso exclusively for Grünenthal. The Company will supply Zalviso at the Company’s fully burdened manufacturing cost (as defined in the Manufacturing Agreement). The Manufacturing Agreement requires the Company to use commercially reasonable efforts to enter stand-by contracts with third party contract manufacturers to ensure continual supply of Zalviso and under certain conditions permits Grünenthal to use a third party back-up manufacturer to manufacture Zalviso for commercial sale in their territories.
	Unless earlier terminated, the Manufacturing Agreement continues in effect until the later of the expiration of the obligation of Grünenthal to make royalty and supply and trademark fee payments or the end of any transition period for manufacturing obligations due to the expiration or termination of the License Agreement. The Manufacturing Agreement is subject to earlier termination in connection with certain termination events in the License Agreement, in the event the parties mutually agree, by a party in the event of an uncured material breach by the other party or upon the bankruptcy or insolvency of either party.
	The Company identified the following four significant non-contingent performance deliverables under the agreements: 1) intellectual property (license), 2) the obligation to provide research and development services, 3) the significant and incremental discount on the manufacturing of Zalviso for commercial purposes, and 4) the obligation to participate on the joint steering committee. The Company developed best estimates of selling prices for each deliverable in order to allocate the non-contingent arrangement consideration to the four units of accounting.
	The Company’s management determined the best estimate of selling price for the license based on Grünenthal’s estimated future cash flows arising from the arrangement. Embedded in the estimate were significant assumptions regarding regulatory expenses, revenue, including potential customer market for the product and product price, costs to manufacture the product and the discount rate. The Company’s management determined the best estimate of selling price of the research and development services and committee participation based on the nature and timing of the services to be performed and in consideration of personnel and other costs incurred in the delivery of the services. For the discount on manufacturing services, the Company’s management estimated the selling price based on the market level of contract manufacturing margin it could have received if it were engaged to supply products to a customer in a separate transaction.
	The Agreements entitle the Company to receive additional payments upon the achievement of certain development and sales milestones. Based on ASC Topic 605-28, Revenue Recognition — Milestone Method, the Company evaluates contingent milestones at the inception of the agreement, and recognizes consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is considered substantive in its entirety. Milestones are events which have the following characteristics: (i) they can be achieved based in whole or in part on either the Company’s performance or on the occurrence of a specific outcome resulting from the Company’s performance, (ii) there was substantive uncertainty at the date the agreement was entered into that the event would be achieved and, (iii) they would result in additional payments due to the Company. A milestone is considered substantive if the following criteria are met: (i) the consideration is commensurate with either (1) the entity’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item (s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (ii) the consideration relates solely to past performance and, (iii) the consideration is reasonable relative to all of the other deliverables and payment terms, including other potential milestone consideration, within the arrangement.

	The substantive milestone payments will be recognized as revenue in their entirety upon the achievement of each substantive milestone. Based on the criteria noted above, the identified substantive milestones in the agreement pertain to post-approval product enhancements, expanded market opportunities and manufacturing efficiencies for Zalviso. Each of these potential achievements is based primarily on the Company’s performance and involves substantive uncertainty as achievement of these milestones requires future research, development and regulatory activities, which are inherently uncertain in nature. The Company determined that the consideration for each milestone was commensurate with the Company’s performance to achieve the milestone, including future research, development, manufacturing and regulatory activities and that the consideration is reasonable relative to all of the other deliverables and payments within the arrangement. Aggregate potential payments for these milestones total $28.5 million.
	In addition to substantive milestones, two milestones associated with the Agreements were deemed not to be substantive. These milestones pertain to regulatory developments for Zalviso in Europe, which Company’s management deemed to be not substantive due to the level of performance associated with future achievement of these milestones. Aggregate potential payments for these milestones total $20.0 million. When achieved, the value of these milestones will be allocated to the four separate units of accounting based on estimated selling prices and recognized as revenue in the period of achievement to the extent the services underlying the separate units of accounting have been performed. The Company anticipates receiving the first milestone payment of $5.0 million in 2014, for the submission of the Marketing Authorization Application for Zalviso to the European Medicines Agency.
	The Agreements also include milestone payments related to specified net sales targets, totaling $171.5 million. The sales-based milestones do not meet the definition of a milestone under ASU 2010-17 because the achievement of these milestones is solely dependent on counter-party performance and not on any performance obligations of the Company.
	The Company allocated the $30.0 million upfront fee across the four deliverables based on estimated selling prices and for the quarter ended December 31, 2013, recognized $27.4 million attributable to the license. The remaining $2.6 million was recorded as deferred revenue at December 31, 2013, to be recognized in future periods to the extent services are performed related to the other non-contingent performance deliverables under the agreements.
	The Company recognized $95,000 of previously deferred revenue related to research and development services under the collaboration agreement during the three months ended March 31, 2014. As of March 31, 2014, the Company had a deferred revenue balance of $2.5 million. There were no milestone payments received or recognized under these Agreements during the three months ended March 31, 2014.

LongTerm_Debt

Long-Term Debt	3 Months Ended
Long-Term Debt	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Long-Term Debt	'
	5. Long-Term Debt
	Hercules Loan and Security Agreements
	In June 2011, AcelRx entered into a Loan and Security Agreement, or the Original Loan Agreement, with Hercules Technology II, L.P. and Hercules Technology Growth Capital, Inc., collectively referred to as Hercules, under which AcelRx borrowed $20.0 million in two tranches of $10.0 million each, represented by secured convertible term promissory notes, or collectively, the Original Notes. The Company’s obligations associated with the agreement were secured by a security interest in substantially all of its assets, other than its intellectual property.
	The Company borrowed the first tranche of $10.0 million upon the closing of the transaction on June 29, 2011 and borrowed the second tranche of $10.0 million in December 2011. The interest rate for each tranche was 8.50%. In connection with the Original Loan Agreement, the Company issued Hercules seven-year warrants to purchase an aggregate of 274,508 shares of common stock at a price of $3.06 per share. See Note 6 “Warrants,” for further description.
	On December 16, 2013, AcelRx entered into an Amended and Restated Loan and Security Agreement, or the Amended Loan Agreement, with Hercules, under which the Company may borrow up to $40.0 million in three tranches. These loans are represented by secured convertible term promissory notes, or collectively, the Amended Notes. The Amended Loan Agreement amends and restates the Original Loan Agreement, as noted above. The Company borrowed the first tranche of $15.0 million upon closing of the transaction on December 16, 2013. The Company used approximately $8.6 million of the proceeds from the first tranche to repay its obligations under the Original Loan Agreement. The Company recorded the new debt at estimated fair value, $14.3 million, as of December 31, 2013.

	The second tranche of the Amended Loan Agreement of up to $10.0 million can be drawn, at the Company’s option, any time prior to June 30, 2014. The third tranche, of up to $15.0 million, can be drawn at any time between December 15, 2014 and March 15, 2015, but only if the Company has obtained approval for Zalviso from the U.S. Food and Drug Administration, or the Milestone. The interest rate for each tranche will be calculated at a rate equal to the greater of either (i) 9.10% plus the prime rate as reported from time to time in The Wall Street Journal minus 5.25%, and (ii) 9.10%. Payments under the Amended Loan Agreement are interest only until April 1, 2015 (which will be extended until January 1, 2016 if the Company achieves the Milestone on or before April 1, 2015) followed by equal monthly payments of principal and interest through the scheduled maturity date on October 1, 2017 (which would be extended until January 1, 2018 if the Company achieves the Milestone on or prior to April 1, 2015), or the Loan Maturity Date. In addition, a final payment equal to $1,700,000 will be due on the Loan Maturity Date, or such earlier date specified in the Amended Loan Agreement. The Company’s obligations under the Amended Loan Agreement are secured by a security interest in substantially all of its assets, other than its intellectual property.
	If the Company prepays the Amended Loan Agreement prior to maturity, it will pay Hercules a prepayment charge, based on a percentage of the then outstanding principal balance, equal to 3% if the prepayment occurs prior to December 16, 2014, 2% if the prepayment occurs after December 16, 2014, but prior to December 16, 2015, or 1% if the prepayment occurs after December 16, 2015.
	Subject to certain conditions and limitations set forth in the Amended Loan Agreement, the Company has the right to convert up to $5.0 million of scheduled principal installments under the Notes into freely tradeable shares of the Company’s common stock, or Common Stock. The number of shares of Common Stock that would be issued upon conversion of the Amended Notes would be equal to the number determined by dividing (x) the product of (A) the principal amount to be paid in shares of Common Stock and (B) 103%, by (y) $9.30 (subject to certain proportional adjustments as provided for in the Amended Loan Agreement).
	The Amended Loan Agreement includes customary affirmative and restrictive covenants, but does not include any financial maintenance covenants, and also includes standard events of default, including payment defaults, breaches of covenants following any applicable cure period, a material impairment in the perfection or priority of Hercules’ security interest or in the value of the collateral, and events relating to bankruptcy or insolvency. Upon the occurrence of an event of default, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and Hercules may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Amended Loan Agreement.
	In connection with the Amended Loan Agreement, the Company issued a warrant to each Lender which, collectively, are exercisable for an aggregate of 176,730 shares of Common Stock and each carry an exercise price of $6.79. See Note 6 “Warrants,” for further description.
	Upon an event of default, including a change of control, Hercules has the option to accelerate repayment of the Amended Loan Agreement, including payment of any applicable prepayment charges, which range from 1%-3% of the outstanding loan balance and accrued interest, as well as a final payment fee of $1.7 million. This option is considered a contingent put option liability, as the holder of the loan may exercise the option in the event of default, and is considered an embedded derivative, which must be valued and separately accounted for in the Company’s financial statements. As the amendment of the loan agreement was considered an extinguishment, the contingent put option liability associated with the Original Loan Agreement, which had an estimated fair value of $32,000 at the time of the amendment, was written off as a part of the loss on extinguishment, and a new contingent put option liability was established. As of March 31, 2014 and December 31, 2013, the estimated fair value of the contingent put option liability was $296,000 and $334,000, respectively, which was determined by using a risk-neutral valuation model, wherein the fair value of the underlying debt facility is estimated both with and without the presence of the default provisions, holding all other assumptions constant. The resulting difference between the two estimated fair values is the estimated fair value of the default provisions, or the contingent put option. The fair value of the underlying debt facility is estimated by calculating the expected cash flows in consideration of an estimated probability of default and expected recovery rate in default, and discounting such cash flows back to the reporting date using a risk-free rate. The contingent put option liability was recorded as a debt discount to the loan and consequently a reduction to the carrying value of the loan. The contingent put option liability is revalued at the end of each reporting period and any change in the fair value is recognized in interest income and other income (expense), net in the condensed statements of comprehensive loss.
	As of March 31, 2014 and December 31, 2013, the Company had outstanding borrowings under the Amended Loan Agreement of $15.0 million. Interest expense related to the Amended Loan Agreement was $472,000 for the three months ended March 31, 2014, $128,000 of which represented amortization of the debt discount. Interest expense related to the Original Loan Agreement was $454,000 for the three months ended March 31, 2013, $108,000 of which represented amortization of the debt discount.

Warrants

Warrants	3 Months Ended
Warrants	Mar. 31, 2014
Text Block [Abstract]	'
Warrants	'
	6. Warrants
	Series A Warrants
	In March 2007, the Company entered into an equipment financing agreement in which the Company issued immediately exercisable and fully vested warrants to purchase 2,500 shares of its Series A convertible preferred stock, or the Series A warrants, with an exercise price of $10.00 per share. The fair value of the Series A warrants on the date of issuance was $1,000, as determined using the Black-Scholes option-pricing model. This fair value was recorded as a convertible preferred stock warrant liability and as a deferred financing cost in other assets. The fair value was remeasured at the end of each reporting period. In connection with the IPO, the Series A warrants were automatically converted into warrants to purchase 3,425 shares of common stock. As a result of the conversion, these common stock warrants were no longer recorded as liabilities and were, therefore, no longer remeasured as of the end of each reporting period.
	As of March 31, 2014, warrants to purchase 3,425 shares of common stock had not been exercised and were still outstanding. These warrants expire in March 2017.
	Pinnacle Warrants
	In September 2008, the Company entered into a $12.0 million loan and security agreement with Pinnacle Ventures. In connection with this loan and security agreement, the Company issued immediately exercisable and fully vested warrants, or the Series B warrants, to purchase 56,250 shares of Series B convertible preferred stock with an exercise price of $16.00 per share which were ultimately converted into warrants to purchase 228,264 shares of common stock with an exercise price of $3.94 per share in connection with the Company’s initial public offering in 2011.
	In February 2013, warrants to purchase 228,264 shares were net exercised, for 58,580 shares of common stock. As of March 31, 2014, no warrants to purchase shares of common stock issued to Pinnacle were outstanding.
	Hercules Warrants
	In connection with the Amended Loan Agreement, executed in December 2013, the Company issued warrants to Hercules which are exercisable for an aggregate of 176,730 shares of Common Stock and each carry an exercise price of $6.79 (the “Warrants”). Each Warrant may be exercised on a cashless basis. The Warrants are exercisable for a term beginning on the date of issuance and ending on the earlier to occur of five years from the date of issuance or the consummation of certain acquisitions of the Company as set forth in the Warrants. The number of shares for which the Warrants are exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in the Warrants. The Company estimated the fair value of these warrants as of the issuance date to be $1.1 million, which was recorded as equity. The fair value of the warrants was calculated using the Black-Scholes option-valuation model, and was based on the strike price of $6.79, the stock price at issuance of $9.67, the five-year contractual term of the warrants, a risk-free interest rate of 1.55%, expected volatility of 71% and 0% expected dividend yield.
	As of March 31, 2014, warrants to purchase 176,730 shares of common stock issued to Hercules had not been exercised and were still outstanding. These warrants expire in December 2018.
	In connection with the Original Loan Agreement with Hercules, executed in June 2011, the Company issued warrants to Hercules to purchase an aggregate of 274,508 shares of common stock at a price of $3.06 per share.
	During June and July 2013, warrants to purchase 274,508 shares were net exercised, for 183,404 shares of common stock.
	2012 Private Placement Warrants
	In connection with the Private Placement, completed in June 2012, the Company issued PIPE warrants to purchase up to 2,630,103 shares of common stock. The per share exercise price of the PIPE warrants was $3.40 which equals the closing consolidated bid price of the Company’s common stock on May 29, 2012, the effective date of the Purchase Agreement. The PIPE warrants issued in the Private Placement became exercisable six months after the issuance date, and expire on the five year anniversary of the initial exercisability date. Under the terms of the PIPE warrants, upon certain transactions, including a merger, tender offer, sale of all or substantially all of the assets of the Company or if a person or group shall become the owner of 50% of the Company’s issued and outstanding common stock, which is outside of the Company’s control, each PIPE warrant holder may elect to receive a cash payment in exchange for the warrant, in an amount determined by application of the Black-Scholes option-pricing model. Accordingly, the PIPE warrants were recorded as a liability at fair value, as determined by the Black-Scholes option-pricing model, and then marked to fair value each reporting period, with changes in estimated fair value recorded through interest income and other income (expense), net in the condensed statements of comprehensive loss. The Black-Scholes assumptions used to value the PIPE warrants are disclosed in Note 2.

	Upon execution of the Purchase Agreement, the fair value of the PIPE warrants was estimated to be $5.8 million, which was recorded as a liability. As of March 31, 2014, the fair value of the PIPE warrants was estimated to be $13.8 million. As of December 31, 2013, the fair value of the PIPE warrants was estimated to be $13.1 million. The change in fair value for the three months ended March 31, 2014 and 2013, which was recorded as other expense, was $0.7 million and $1.8 million, respectively.
	During the three months ended March 31, 2014, no warrants were exercised for shares of common stock. As of March 31, 2014, PIPE warrants to purchase 1,494,514 shares of common stock issued in connection with the Private Placement had not been exercised and were outstanding. These warrants expire in November 2017.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
Stock-Based Compensation	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-Based Compensation	'
	7. Stock-Based Compensation
	The Company recorded total stock-based compensation expense for stock options, stock awards and the 2011 Employee Stock Purchase Plan as follows (in thousands):


		Three Months Ended
		March 31,
		2014		2013
	Expenses:
	Research and development	$	479	$	355
	General and administrative		496		402

	Total stock-based compensation expense	$	975	$	757

	As of March 31, 2014 there were 1,671,596 shares available for grant, 5,083,428 options outstanding and 0 restricted stock units outstanding under the Company’s 2011 Equity Incentive Plan.

Net_Loss_per_Share_of_Common_S

Net Loss per Share of Common Stock	3 Months Ended
Net Loss per Share of Common Stock	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Net Loss per Share of Common Stock	'
	8. Net Loss per Share of Common Stock
	The following table sets forth the computation of the Company’s basic and diluted net loss per share of common stock during the three months ended March 31, 2014 and 2013 (in thousands, except for share and per share amounts):


		Three Months Ended
		March 31,
		2014			2013
	Net loss	$	(9,631	)	$	(12,762	)

	Shares used in computing net loss per share of common stock, basic and diluted		43,190,409			37,133,358

	Net loss per share of common stock, basic and diluted	$	(0.22	)	$	(0.34	)

	The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive:


		March 31,
		2014			2013
	Stock options to purchase common stock		5,083,428			5,077,513
	Restricted stock units		—			65,765
	Common stock warrants		1,674,669			2,908,036

Manufacturing_Agreements

Manufacturing Agreements	3 Months Ended
Manufacturing Agreements	Mar. 31, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Manufacturing Agreements	'
	9. Manufacturing Agreements
	Patheon
	In January 2013, the Company and Patheon Pharmaceuticals Inc., or Patheon, entered into a Manufacturing Services Agreement, or the Services Agreement, and a related Amended and Restated Capital Expenditure and Equipment Agreement, or the Capital Agreement, relating to the manufacture of sufentanil tablets, or the Product, for use with the Company’s sufentanil sublingual tablet system, or ARX-01.

	Under the terms of the Services Agreement, the Company has agreed to purchase, subject to Patheon’s continued material compliance with the terms of the Services Agreement, all of its Product requirements for the United States, Canada and Mexico from Patheon during the Initial Term of the Services Agreement (as defined below), and at least eighty percent (80%) of its Product requirements for such territories after the Initial Term.
	The term of the Services Agreement extends until December 31, 2017, or the Initial Term, and will automatically renew thereafter for periods of two years, unless terminated by either party upon eighteen months’ prior written notice; provided, however, that the Services Agreement may not be terminated without cause prior to the end of the Initial Term.
	The Company also entered into a Capital Expenditure and Equipment Agreement, or the Capital Agreement. Under the terms of the Capital Agreement, as amended in January 2014, the Company has made and continues to make certain modifications to Patheon’s Cincinnati facility, the aggregate cost of which is expected to be less than $4.4 million and which is the responsibility of the Company. Property and equipment, net in the condensed balance sheet at March 31, 2014, includes $2.8 million related to certain modifications the Company is making at Patheon’s Cincinnati facility under the terms of the Capital Agreement.
	Expenditures associated with the aforementioned agreements are primarily driven by the potential commercial requirements and demand for the Company’s products, none of which have been approved for commercialization; accordingly, the amounts and timing of such future expenditures cannot be determined at this time.
	Grünenthal
	On December 16, 2013, AcelRx and Grünenthal entered into a Collaboration and License Agreement (the “License Agreement”) and related Manufacture and Supply Agreement (the “Manufacturing Agreement” and together with the License Agreement, the “Grünenthal Agreements”). The License Agreement grants Grünenthal rights to commercialize Zalviso in the EU, Switzerland, Liechtenstein, Iceland, Norway and Australia, for pain treatment within or dispensed by hospitals hospices, nursing homes and other medically-supervised settings.
	Under the terms of the Manufacturing Agreement, the Company will manufacture and supply Zalviso exclusively for Grünenthal. The Company will supply Zalviso at the Company’s fully burdened manufacturing cost (as defined in the Manufacturing Agreement). The Manufacturing Agreement requires the Company to use commercially reasonable efforts to enter stand-by contracts with third party contract manufacturers to ensure a continual supply of Zalviso and under certain conditions permits Grünenthal to use a third party back-up manufacturer to manufacture Zalviso for commercial sale in their territories.
	Unless earlier terminated, the Manufacturing Agreement continues in effect until the later of the expiration of the obligation of Grünenthal to make royalty and supply and trademark fee payments or the end of any transition period for manufacturing obligations due to the expiration or termination of the License Agreement. The Manufacturing Agreement is subject to earlier termination in connection with certain termination events in the License Agreement, in the event the parties mutually agree, by a party in the event of an uncured material breach by the other party or upon the bankruptcy or insolvency of either party.
	Under the Supply Agreement, the Company will exclusively manufacture and supply Zalviso to Grünenthal for commercial sale in their territories.
	Expenditures associated with the aforementioned agreements are primarily driven by the potential commercial requirements and demand for the Company’s products, none of which are currently approved for commercial use; accordingly, the amounts and timing of such future expenditures cannot be determined at this time.

Subsequent_Event

Subsequent Event	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Event	'
	10. Subsequent Event
	In May 2014, the Company entered into an amendment, or the Lease Amendment, to that certain lease dated December 21, 2011, with Metropolitan Life Insurance Company, or the Existing Lease, for 13,787 square feet of space located at 301 Galveston Drive, Redwood City, California, or the Current Premises. Pursuant to the Lease Amendment, the term of the Existing Lease has been extended for a period of twenty (20) months and twenty-two (22) days and expiring January 31, 2018, or the Expiration Date, unless sooner terminated pursuant to the terms of the Existing Lease. In addition, the Lease Amendment included a new lease on an additional 12,106 square feet of office space, or the Expansion Space, which is adjacent to the current premises. The new lease for the Expansion Space has a term of 42 months commencing on August 1, 2014, and expiring on the Expiration Date. The Company has an option to extend the term of the Lease Amendment for an additional five years, which would commence upon the Expiration Date, at a market rate determined according to the Existing Lease.


	Base rent payable under the Lease Amendment during the Extended Term for the Current Premises will be as follows:


	Period from/to	Monthly Base
		Rent
	May 9, 2016 to May 8, 2017	$	35,961.55
	May 9, 2017 to January 31, 2018		37,040.40
	Base rent payable under the Lease Amendment for the Expansion Space, commencing August 1, 2014, will be as follows:


	Months of Lease Term	Monthly Base
		Rent
	12-Jan	$	23,001.40
	13-24		23,691.44
	25-36		24,402.18
	37-42		25,134.25
	In addition, the Company will pay the Landlord specified percentages of certain operating expenses and taxes related to the leased facility incurred by the Landlord.

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
The Company	'
	The Company
	AcelRx Pharmaceuticals, Inc., or the Company or AcelRx, was incorporated in Delaware on July 13, 2005 as SuRx, Inc., and in January 2006, the Company changed its name to AcelRx Pharmaceuticals, Inc. The Company’s operations are based in Redwood City, California.
	AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx intends to commercialize its product candidates in the United States and license the development and commercialization rights to its product candidates for sale outside of the United States through strategic partnerships and collaborations. The Company’s lead product candidate, ZalvisoTM, formerly known as the Sufentanil NanoTab patient-controlled analgesia, or PCA, System, or ARX-01. The New Drug Application, or NDA, for Zalviso is currently under review by the FDA. The proposed indication for Zalviso is for the management of moderate-to-severe acute pain in adult patients in the hospital setting. In addition, in December 2013, the Company entered into a collaboration agreement with Grünenthal, a European-based pharmaceutical company, for the commercialization of Zalviso in Europe and Australia. We anticipate the filing of the Marketing Authorization Application, or MAA, for Zalviso under the centralized procedure in the European Union, or EU, in mid-2014.
	The Company has incurred recurring operating losses and negative cash flows from operating activities since inception and expects to continue to incur negative cash flows until its product candidates are approved for marketing in the United States and other countries, in which it has and intends to license its products, which may never occur. In previous years, prior to the completion of the clinical development program for Zalviso and the commercial collaboration of Zalviso, AcelRx was considered a development stage company.
	The Company has one business activity, which is the development and commercialization of product candidates for the treatment of pain, and a single reporting and operating unit structure.
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and the rules and regulations of the U.S. Securities and Exchange Commission, or SEC. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.
	Operating results for the three months ended March 31, 2014, are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. The condensed balance sheet as of December 31, 2013, was derived from the Company’s audited financial statements as of December 31, 2013, included in the Company’s Annual Report on Form 10-K filed with the SEC. These financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, which includes a broader discussion of the Company’s business and the risks inherent therein.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements and accompanying notes. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.
Newly Adopted Accounting Pronouncements	'
	Newly Adopted Accounting Pronouncements
	There have been no recent accounting pronouncements or changes in accounting pronouncements during the three months ended March 31, 2014, as compared to the recent accounting pronouncements described in the Company’s Form 10-K for the year ended December 31, 2013, that are of significance, or potential significance to the Company.

Investments_and_Fair_Value_Mea1

Investments and Fair Value Measurement (Tables)	3 Months Ended
Investments and Fair Value Measurement (Tables)	Mar. 31, 2014
Text Block [Abstract]	'
Summary of Cash, Cash Equivalents and Investments	'
	The table below summarizes the Company’s cash, cash equivalents and investments (in thousands):


		As of March 31, 2014
		Amortized Cost			Gross Unrealized		Gross Unrealized		Fair
		Amortized Cost			Gains		Losses		Value
	Cash and cash equivalents:
	Cash	$	77,582		$	—	$	—	$	77,582
	Money market funds		5			—		—		5

	Total cash and cash equivalents		77,587			—		—		77,587
	Marketable securities:
	U.S. government agency securities		15,288			1		—	$	15,289

	Total marketable securities		15,288			1		—	$	15,289

	Total cash, cash equivalents and investments	$	92,875		$	1	$	—	$	92,876


		As of December 31, 2013
		Amortized Cost			Gross Unrealized		Gross Unrealized		Fair
		Amortized Cost			Gains		Losses		Value
	Cash and cash equivalents:
	Cash	$	88,390		$	—	$	—	$	88,390
	Money market funds		11			—		—		11

	Total cash and cash equivalents		88,401			—		—	$	88,401
	Marketable securities:
	U.S. government agency securities		15,261			1		—		15,262

	Total marketable securities		15,261			1		—	$	15,262

	Total cash, cash equivalents and investments	$	103,662		$	1	$	—	$	103,663
Fair Value of Financial Assets and Liabilities by Level within Fair Value Hierarchy	'
	The following table sets forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands):


		As of March 31, 2014
		Fair Value			Level I		Level II		Level III
	Assets
	Money market funds	$	5		$	5	$	—	$	—
	U.S. government agency obligations		15,289			—		15,289		—

	Total assets measured at fair value	$	15,294		$	5	$	15,289	$	—

	Liabilities
	PIPE warrants	$	13,795			—		—	$	13,795
	Contingent put option liability		296			—		—		296

	Total liabilities measured at fair value	$	14,091		$	—	$	—	$	14,091


		As of December 31, 2013
		Fair Value			Level I		Level II		Level III
	Assets
	Money market funds	$	11		$	11	$	—	$	—
	U.S. government agency obligations		15,262			—		15,262		—

	Total assets measured at fair value	$	15,273		$	11	$	15,262	$	—

	Liabilities
	PIPE warrants	$	13,111			—		—	$	13,111
	Contingent put option liability	$	334			—		—	$	334

	Total liabilities measured at fair value	$	13,445		$	—	$	—	$	13,445

Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of PIPE Warrants	'
	The following table sets forth the assumptions used in the Black-Scholes option-pricing model to estimate the fair value of the PIPE warrants as of March 31, 2014:


	Market price	$	12.01
	Exercise price	$	3.4
	Risk-free interest rate		0.9	%
	Expected volatility		64	%
	Expected life (in years)		3.7
	Expected dividend yield		0	%

	The following table sets forth the assumptions used in the Black-Scholes option-pricing model to estimate the fair value of the PIPE warrants as of December 31, 2013:


	Market price	$	11.31
	Exercise price	$	3.4
	Risk-free interest rate		1.27	%
	Expected volatility		69	%
	Expected life (in years)		3.92
	Expected dividend yield		0	%
Summary of Changes in Fair Value of Level III Financial Liabilities	'
	The following tables set forth a summary of the changes in the fair value of the Company’s Level III financial liabilities for the three months ended March 31, 2014 and March 31, 2013 (in thousands):


		Three Months
		Ended
		March 31,
		2014
	Fair value—beginning of period	$	13,445
	Change in fair value of PIPE warrants		684
	Change in fair value of contingent put option associated with Amended Loan Agreement with Hercules		(38	)

	Fair value—end of period	$	14,091


		Three Months
		Ended
		March 31,
		2013
	Fair value—beginning of period	$	7,500
	Change in fair value of PIPE warrants		1,776
	Change in fair value of contingent put option associated with Original Loan Agreement with Hercules		(22	)

	Fair value—end of period	$	9,254

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
Stock-Based Compensation (Tables)	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Employee Stock Purchase Plan	'
	The Company recorded total stock-based compensation expense for stock options, stock awards and the 2011 Employee Stock Purchase Plan as follows (in thousands):


		Three Months Ended
		March 31,
		2014		2013
	Expenses:
	Research and development	$	479	$	355
	General and administrative		496		402

	Total stock-based compensation expense	$	975	$	757

Net_Loss_per_Share_of_Common_S1

Net Loss per Share of Common Stock (Tables)	3 Months Ended
Net Loss per Share of Common Stock (Tables)	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Computation of Basic and Diluted Net Loss per Share of Common Stock	'
	The following table sets forth the computation of the Company’s basic and diluted net loss per share of common stock during the three months ended March 31, 2014 and 2013 (in thousands, except for share and per share amounts):


		Three Months Ended
		March 31,
		2014			2013
	Net loss	$	(9,631	)	$	(12,762	)

	Shares used in computing net loss per share of common stock, basic and diluted		43,190,409			37,133,358

	Net loss per share of common stock, basic and diluted	$	(0.22	)	$	(0.34	)

Outstanding Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share	'
	The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive:


		March 31,
		2014			2013
	Stock options to purchase common stock		5,083,428			5,077,513
	Restricted stock units		—			65,765
	Common stock warrants		1,674,669			2,908,036

Subsequent_Event_Tables

Subsequent Event (Tables)	3 Months Ended
	Mar. 31, 2014
Lease Extended Term	'
Schedule of Base Rent Payable Under Lease Amendment	'
	Base rent payable under the Lease Amendment during the Extended Term for the Current Premises will be as follows:


	Period from/to	Monthly Base
		Rent
	May 9, 2016 to May 8, 2017	$	35,961.55
	May 9, 2017 to January 31, 2018		37,040.40
Lease Expansion Space	'
Schedule of Base Rent Payable Under Lease Amendment	'
	Base rent payable under the Lease Amendment for the Expansion Space, commencing August 1, 2014, will be as follows:


	Months of Lease Term	Monthly Base
		Rent
	12-Jan	$	23,001.40
	13-24		23,691.44
	25-36		24,402.18
	37-42		25,134.25

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Place of incorporation	'Delaware
Date of incorporation	13-Jul-05

Investments_and_Fair_Value_Mea2

Investments and Fair Value Measurement - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Investment Holdings [Line Items]	'	'	'
Maturity period of non-current marketable securities	'Beyond one year	'	'
Unrealized losses on available-for-sale securities	$0	'	$0
Realized gains or losses in available-for-sale of securities	0	0	'
Other than temporary impairment for available-for-sale securities	0	'	0
Amounts reclassified out of other comprehensive income to earnings	$0	$0	'
Maximum	'	'	'
Investment Holdings [Line Items]	'	'	'
Contractual maturity period for all investments	'1 year	'	'1 year

Summary_of_Cash_Cash_Equivalen

Summary of Cash, Cash Equivalents and Investments (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Amortized Cost	$92,875	$103,662
Gross Unrealized Gains	1	1
Gross Unrealized Losses	'	'
Fair Value	92,876	103,663
Cash and cash equivalents	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Amortized Cost	77,587	88,401
Gross Unrealized Gains	'	'
Gross Unrealized Losses	'	'
Fair Value	77,587	88,401
Cash and cash equivalents \| Cash	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Amortized Cost	77,582	88,390
Gross Unrealized Gains	'	'
Gross Unrealized Losses	'	'
Fair Value	77,582	88,390
Cash and cash equivalents \| Money market funds	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Amortized Cost	5	11
Gross Unrealized Gains	'	'
Gross Unrealized Losses	'	'
Fair Value	5	11
Marketable securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Amortized Cost	15,288	15,261
Gross Unrealized Gains	1	1
Gross Unrealized Losses	'	'
Fair Value	15,289	15,262
Marketable securities \| U.S. government agency securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Amortized Cost	15,288	15,261
Gross Unrealized Gains	1	1
Gross Unrealized Losses	'	'
Fair Value	$15,289	$15,262

Fair_Value_of_Financial_Assets

Fair Value of Financial Assets and Liabilities by Level within Fair Value Hierarchy (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets measured at fair value	$15,294	$15,273
Total liabilities measured at fair value	14,091	13,445
Contingent put option liability	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total liabilities measured at fair value	296	334
PIPE warrants	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total liabilities measured at fair value	13,795	13,111
Money market funds	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets measured at fair value	5	11
U.S. government agency obligations	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets measured at fair value	15,289	15,262
Level I	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets measured at fair value	5	11
Total liabilities measured at fair value	'	'
Level I \| Contingent put option liability	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total liabilities measured at fair value	'	'
Level I \| PIPE warrants	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total liabilities measured at fair value	'	'
Level I \| Money market funds	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets measured at fair value	5	11
Level I \| U.S. government agency obligations	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets measured at fair value	'	'
Level II	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets measured at fair value	15,289	15,262
Total liabilities measured at fair value	'	'
Level II \| Contingent put option liability	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total liabilities measured at fair value	'	'
Level II \| PIPE warrants	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total liabilities measured at fair value	'	'
Level II \| Money market funds	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets measured at fair value	'	'
Level II \| U.S. government agency obligations	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets measured at fair value	15,289	15,262
Level III	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets measured at fair value	'	'
Total liabilities measured at fair value	14,091	13,445
Level III \| Contingent put option liability	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total liabilities measured at fair value	296	334
Level III \| PIPE warrants	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total liabilities measured at fair value	13,795	13,111
Level III \| Money market funds	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets measured at fair value	'	'
Level III \| U.S. government agency obligations	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets measured at fair value	'	'

Assumptions_Used_in_BlackSchol

Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of PIPE Warrants (Detail) (PIPE warrants, USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
PIPE warrants	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Market price	$12.01	$11.31
Exercise price	$3.40	$3.40
Risk-free interest rate	0.90%	1.27%
Expected volatility	64.00%	69.00%
Expected life (in years)	'3 years 8 months 12 days	'3 years 11 months 1 day
Expected dividend yield	0.00%	0.00%

Summary_of_Changes_in_Fair_Val

Summary of Changes in Fair Value of Level III Financial Liabilities (Detail) (Level III, USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Fair value-beginning of period	$13,445	$7,500
Change in fair value of PIPE warrants	684	1,776
Fair value-end of period	14,091	9,254
Amended Loan Agreement with Hercules	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Change in fair value of contingent put option	-38	'
Original Loan Agreement with Hercules	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Change in fair value of contingent put option	'	($22)

Research_Grant_Agreement_Addit

Research Grant Agreement - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		12 Months Ended
	31-May-11	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Research And Development [Abstract]	'	'	'	'
Attributable revenue for product development from US Army Medical Research and Material Command	$5,600,000	'	'	$5,600,000
Research grant revenue	'	$0	$940,000	'

Collaboration_Agreement_Additi

Collaboration Agreement - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
		Zalviso	Zalviso	Up Front Fee
			Europe
Revenue Recognition, Milestone Method [Line Items]	'	'	'	'
Aggregate potential payments	$30,000,000	$28,500,000	$20,000,000	'
Additional payments receivable	220,000,000	'	'	'
Revenue recognition - milestone method	'Milestones are events which have the following characteristics: (i) they can be achieved based in whole or in part on either the Companybs performance or on the occurrence of a specific outcome resulting from the Companybs performance, (ii) there was substantive uncertainty at the date the agreement was entered into that the event would be achieved and, (iii) they would result in additional payments due to the Company. A milestone is considered substantive if the following criteria are met: (i) the consideration is commensurate with either (1) the entitybs performance to achieve the milestone, or (2) the enhancement of the value of the delivered item (s) as a result of a specific outcome resulting from the entitybs performance to achieve the milestone, (ii) the consideration relates solely to past performance and, (iii) the consideration is reasonable relative to all of the other deliverables and payment terms, including other potential milestone consideration, within the arrangement.	'	'	'
First milestone payment to be received	'	'	5,000,000	'
Milestone payments related to net sales net sales target	171,500,000	'	'	'
License revenue recognized	'	'	'	27,400,000
Deferred revenue	2,500,000	'	'	2,600,000
Recognized deferred revenue related to research and development	95,000	'	'	'
Milestone payments received	$0	'	'	'

LongTerm_Debt_Additional_Infor

Long-Term Debt - Additional Information (Detail) (USD $)

3 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Jun. 30, 2011

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Dec. 16, 2013

Jun. 29, 2011

Mar. 31, 2014

Jun. 29, 2011

Dec. 31, 2011

Mar. 31, 2014

Dec. 31, 2013

Dec. 16, 2013

Mar. 31, 2014

Dec. 16, 2013

Mar. 31, 2014

Hercules Warrants

Hercules Loan and Security Agreements

Amended and Restated Loan and Security Agreement

Tranche

Hercules Warrants

Prior to December 16, 2014

After December 16, 2014, but Prior to December 16, 2015

After December 16, 2015

Maximum

Minimum

First Tranche

Second Tranche

Prime Rate

First Tranche

Second Tranche

Third Tranche

Debt Instrument [Line Items]

Loan and security agreement

$20,000,000

$10,000,000

$15,000,000

Number of tranches

Warrants exercisable term

'5 years

'7 years

Debt, interest rate percentage

8.50%

Warrants exercise price per share

$3.06

$6.79

$3.06

Warrants to purchase common stock

274,508

Maximum borrowing capacity

40,000,000

10,000,000

15,000,000

Proceeds used for repayment of obligation

1,893,000

8,600,000

New debt at estimated fair value

14,300,000

Payment terms

'Payments under the Loan Agreement are interest only until April 1, 2015 (which will be extended until January 1, 2016 if the Company achieves the Milestone on or before April 1, 2015) followed by equal monthly payments of principal and interest through the scheduled maturity date on October 1, 2017 (which would be extended until January 1, 2018 if the Company achieves the Milestone on or prior to April 1, 2015) (the "Loan Maturity Date").

Interest rate terms

'The interest rate for each tranche will be calculated at a rate equal to the greater of either (i) 9.10% plus the prime rate as reported from time to time in The Wall Street Journal minus 5.25%, and (ii) 9.10%.

Interest rate

9.10%

Basis spread on variable interest rate

5.25%

Final payment due on maturity date

1,700,000

Prepayment terms

'If the Company prepays the loan prior to maturity, it will pay the Lenders a prepayment charge, based on a percentage of the then outstanding principal balance, equal to 3% if the prepayment occurs prior to December 16, 2014, 2% if the prepayment occurs after December 16, 2014, but prior to December 16, 2015, or 1% if the prepayment occurs after December 16, 2015.

Prepayment charge on loan percentage

3.00%

2.00%

1.00%

Convertible debt amount

5,000,000

Convertible debt terms

'Subject to certain conditions and limitations set forth in the Loan Agreement, the Company has the right to convert up to $5.0 million of scheduled principal installments under the Notes into freely tradeable shares of the Companybs common stock (bCommon Stockb). The number of shares of Common Stock that would be issued upon conversion of the Notes would be equal to the number determined by dividing (x) the product of (A) the principal amount to be paid in shares of Common Stock and (B) 103%, by (y) $9.30 (subject to certain proportional adjustments as provided for in the Loan Agreement).

Default interest rate

5.00%

Warrants outstanding

176,730

Prepayment charges for accelerated repayment of credit facility, percentage of outstanding balance

3.00%

1.00%

Final payment fee for early repayment of facility

1,700,000

Contingent put option liability

296,000

334,000

32,000

Loan and security agreement, amount outstanding

15,000,000

Amortization of debt discounts

128,000

108,000

Interest expense

$472,000

$454,000

$472,000

$454,000

Warrants_Additional_Informatio

Warrants - Additional Information (Detail) (USD $)

3 Months Ended

1 Months Ended

2 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

Mar. 31, 2014

Jun. 30, 2011

Jul. 31, 2013

Mar. 31, 2014

Feb. 28, 2013

Mar. 31, 2014

Sep. 30, 2008

Mar. 31, 2014

Jun. 30, 2012

Mar. 31, 2014

Mar. 31, 2007

Mar. 31, 2014

Mar. 31, 2007

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Hercules Warrants

Pinnacle [Member]

PIPE warrants

Series Warrants

2012 Private Placement

Pinnacle Loan and Security Agreement

Series B Preferred Stock

Series C Convertible Preferred Stock

Series A Preferred Stock

Common Stock

Class of Warrant or Right [Line Items]

PIPE warrants to purchase shares

274,508

56,250

228,264

3,425

2,500

PIPE warrants, exercise price per share

$3.06

$6.79

$16

$3.94

$3.40

$10

Fair value of warrants

$1,100,000

$1,000

Warrants outstanding

176,730

2,630,103

3,425

1,494,514

Warrants, expiration date

'2017-03-01

Loan and security agreement, maximum potential borrowings

12,000,000

Common stock warrants exercised

274,508

228,264

Common stock issued upon exercise of warrants

183,404

58,580

Warrants exercisable term

'5 years

'6 months

Warrants strike price

6.79

Warrants stock issuance price

9.67

Risk-free interest rate

1.55%

Expected volatility

71.00%

Expected dividend yield

0.00%

Warrants, expiration date

31-Dec-18

1-Nov-17

Warrant expiration period after the initial exercisability date

'5 years

Exercise of warrants description

'Under the terms of the PIPE warrants, upon certain transactions, including a merger, tender offer, sale of all or substantially all of the assets of the Company or if a person or group shall become the owner of 50% of the Company's issued and outstanding common stock, which is outside of the Company's control, each PIPE warrant holder may elect to receive a cash payment in exchange for the warrant, in an amount determined by application of the Black-Scholes option-pricing model.

Estimated fair value of PIPE warrants upon execution of Purchase Agreement

5,800,000

Estimated fair value of PIPE warrants at end of period

13,800,000

13,100,000

Expense recorded related to change in fair value of PIPE warrants

$700,000

$1,800,000

Employee_Stock_Purchase_Plan_D

Employee Stock Purchase Plan (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock-based compensation expense	$975	$757
Research and development	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock-based compensation expense	479	355
General and administrative	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock-based compensation expense	$496	$402

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail)	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Shares available for grant	1,671,596
Number of stock options outstanding	5,083,428
Restricted stock unit outstanding	0

Computation_of_Basic_and_Dilut

Computation of Basic and Diluted Net Loss per Share of Common Stock (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Earnings Per Share [Abstract]	'	'
Net loss	($9,631)	($12,762)
Shares used in computing net loss per share of common stock, basic and diluted	43,190,409	37,133,358
Net loss per share of common stock, basic and diluted	($0.22)	($0.34)

Outstanding_Shares_of_Common_S

Outstanding Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share (Detail)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Stock options to purchase common stock	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Shares of common stock equivalents excluded from the computation of diluted net loss per share of common stock	5,083,428	5,077,513
Restricted stock units	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Shares of common stock equivalents excluded from the computation of diluted net loss per share of common stock	'	65,765
Common stock warrants	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Shares of common stock equivalents excluded from the computation of diluted net loss per share of common stock	1,674,669	2,908,036

Manufacturing_Agreements_Addit

Manufacturing Agreements - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Long-term Purchase Commitment [Line Items]	'	'
Service agreement date	'2013-01	'
Product requirement percentage under Services Agreement	80.00%	'
Service agreement expiration date	31-Dec-17	'
Services Agreement renewal period	'2 years	'
Services Agreement termination notice period	'18 months	'
Maximum aggregate cost expected to incur under Capital Agreement	$4,400,000	'
Property and equipment, net	6,160,000	5,179,000	[1]
Patheon's Cincinnati Facility	'	'
Long-term Purchase Commitment [Line Items]	'	'
Property and equipment, net	$2,800,000	'

[1]	The condensed balance sheet as of December 31, 2013 has been derived from the audited financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2013.

Subsequent_Event_Additional_In

Subsequent Event - Additional Information (Detail) (Subsequent Event)	1 Months Ended
	31-May-14
	sqft
Lease Extended Term	'
Subsequent Event [Line Items]	'
Area of premises leased under lease agreement	13,787
Extended term of lease agreement	'20 months 22 days
Lease expiration date	31-Jan-18
Lease Expansion Space	'
Subsequent Event [Line Items]	'
Area of premises leased under lease agreement	12,106
Term of lease agreement	'42 months
Lease commencement date	1-Aug-14

Subsequent_Event_Schedule_of_B

Subsequent Event - Schedule of Base Rent Payable Under Lease Amendment (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014
Lease Extended Term \| May 9, 2016 to May 8, 2017	'
Operating Leased Assets [Line Items]	'
Monthly Base Rent payable	$35,961.55
Lease Extended Term \| May 9, 2017 to January 31, 2018	'
Operating Leased Assets [Line Items]	'
Monthly Base Rent payable	37,040.40
Lease Expansion Space	'
Operating Leased Assets [Line Items]	'
Lease Term Months from 1-12	23,001.40
Lease Term Months from 13-24	23,691.44
Lease Term Months from 25-36	24,402.18
Lease Term Months from 37-42	$25,134.25